Literature DB >> 12652293

Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.

Vladimir Y Bogdanov1, Viji Balasubramanian, James Hathcock, Oana Vele, Mark Lieb, Yale Nemerson.   

Abstract

Tissue factor (TF) is an essential enzyme activator that forms a catalytic complex with FVII(a) and initiates coagulation by activating FIX and FX, ultimately resulting in thrombin formation. TF is found in adventitia of blood vessels and the lipid core of atherosclerotic plaques. In unstable coronary syndromes, plaque rupture initiates coagulation by exposing TF to blood. Biologically active TF has been detected in vessel walls and circulating blood. Elevated intravascular TF has been reported in diverse pro-thrombotic syndromes such as myocardial infarction, sepsis, anti-phospholipid syndrome and sickle-cell disease. It is unclear how TF circulates, although it may be present in pro-coagulant microparticles. We now report identification of a form of human TF generated by alternative splicing. Our studies indicate that alternatively spliced human tissue factor (asHTF) contains most of the extracellular domain of TF but lacks a transmembrane domain and terminates with a unique peptide sequence. asHTF is soluble, circulates in blood, exhibits pro-coagulant activity when exposed to phospholipids, and is incorporated into thrombi. We propose that binding of asHTF to the edge of thrombi contributes to thrombus growth by creating a surface that both initiates and propagates coagulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12652293     DOI: 10.1038/nm841

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  90 in total

Review 1.  Tissue factor controversies.

Authors:  Kenneth G Mann; Jolanta Krudysz-Amblo; Saulius Butenas
Journal:  Thromb Res       Date:  2012-03-07       Impact factor: 3.944

2.  Blood-born tissue factor in cardiovascular disease: where are we now?

Authors:  Vincenzo Toschi
Journal:  Intern Emerg Med       Date:  2010-09-18       Impact factor: 3.397

Review 3.  The harms and benefits of inflammatory and immune responses in vascular disease.

Authors:  Angel Chamorro; John Hallenbeck
Journal:  Stroke       Date:  2006-01-12       Impact factor: 7.914

4.  Tissue factor–dependent procoagulant activity of subtilase cytotoxin, a potent AB5 toxin produced by shiga toxigenic Escherichia coli.

Authors:  Hui Wang; James C Paton; Cheleste M Thorpe; Claudine S Bonder; Wai Yan Sun; Adrienne W Paton
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

5.  Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively.

Authors:  Mikhail A Panteleev; Mikhail V Ovanesov; Dmitrii A Kireev; Aleksei M Shibeko; Elena I Sinauridze; Natalya M Ananyeva; Andrey A Butylin; Evgueni L Saenko; Fazoil I Ataullakhanov
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

6.  Splice variants of tissue factor promote monocyte-endothelial interactions by triggering the expression of cell adhesion molecules via integrin-mediated signaling.

Authors:  R Srinivasan; E Ozhegov; Y W van den Berg; B J Aronow; R S Franco; M B Palascak; J T Fallon; W Ruf; H H Versteeg; V Y Bogdanov
Journal:  J Thromb Haemost       Date:  2011-10       Impact factor: 5.824

7.  Blood coagulation and blood vessel development: is tissue factor the missing link?

Authors:  Nigel Mackman; George E Davis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

8.  Confinement regulates complex biochemical networks: initiation of blood clotting by "diffusion acting".

Authors:  Feng Shen; Rebecca R Pompano; Christian J Kastrup; Rustem F Ismagilov
Journal:  Biophys J       Date:  2009-10-21       Impact factor: 4.033

Review 9.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 10.  Biomolecular markers of cancer-associated thromboembolism.

Authors:  Diana L Hanna; Richard H White; Ted Wun
Journal:  Crit Rev Oncol Hematol       Date:  2013-03-21       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.